OHR Pharmaceutical Inc - Company & Market Research Reports

Ohr Pharmaceutical is a pharmaceutical company focused on the development of novel therapeutics for the treatment of ocular diseases. Its lead clinical program is its OHR-102 (Squalamine) eye drops, a small molecule anti-angiogenic drug that provides a non-invasive therapy to enhance vision. It could be used in the treatment of retinal diseases, including wet age related macular degeneration (AMD), retinal vein occlusion and diabetic retinopathy. OHR Pharmaceutical is headquartered in New York.

From
From
From
From
From
From
From
From
From
Glaucoma - Pipeline Review, H1 2018 - Product Thumbnail Image

Glaucoma - Pipeline Review, H1 2018

  • Drug Pipelines
  • 299 Pages
From
From
Wet AMD- Pipeline Insight, 2018 - Product Thumbnail Image

Wet AMD- Pipeline Insight, 2018

  • Drug Pipelines
  • 106 Pages
From
Retinal Degeneration - Pipeline Insight, 2018 - Product Thumbnail Image

Retinal Degeneration - Pipeline Insight, 2018

  • Drug Pipelines
  • 217 Pages
From
From
From
Glaucoma - Pipeline Review, H2 2018 - Product Thumbnail Image

Glaucoma - Pipeline Review, H2 2018

  • Drug Pipelines
  • 308 Pages
From
From
From
From
Loading Indicator
adroll